These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17237696)

  • 1. Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab.
    Garibaldi DC; Adler RA
    Ophthalmic Plast Reconstr Surg; 2007; 23(1):62-3. PubMed ID: 17237696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Periocular cutaneous toxicity and cicatricial ectropion: a potential class effect of antineoplastic agents that inhibit EGFR signaling.
    Frankfort BJ; Garibaldi DC
    Ophthalmic Plast Reconstr Surg; 2007; 23(6):496-7. PubMed ID: 18030130
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversible cicatricial ectropion associated with EGFR inhibitors.
    Scofield-Kaplan S; Todaro J; Winn BJ
    Orbit; 2018 Oct; 37(5):364-367. PubMed ID: 29336655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of amniotic membrane graft in the surgical management of cicatricial ectropion associated with cetuximab therapy.
    Vinod K; Diaz V
    J Surg Case Rep; 2015 Jan; 2015(1):. PubMed ID: 25576167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.
    Takahashi N; Yamada Y; Furuta K; Nagashima K; Kubo A; Sasaki Y; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Hamaguchi T; Shimada Y
    Cancer Sci; 2015 May; 106(5):604-10. PubMed ID: 25707609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer.
    Jin HD; Blessing NW
    Am J Ophthalmol Case Rep; 2020 Sep; 19():100810. PubMed ID: 32642599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Patel DK
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous toxicity from epidermal growth factor receptor inhibitors: would a subcutaneous desensitization be helpful? Case report.
    D'Alessio A; Cecchini S; Di Mauro D; Geroli L; Villa S; Quadri A; Resta D; Fortugno C
    Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27791234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
    Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
    J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target.
    Meropol NJ
    J Clin Oncol; 2005 Mar; 23(9):1791-3. PubMed ID: 15677698
    [No Abstract]   [Full Text] [Related]  

  • 15. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.
    Ouwerkerk J; Boers-Doets C
    Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
    Troiani T; Martinelli E; Napolitano S; Vitagliano D; Ciuffreda LP; Costantino S; Morgillo F; Capasso A; Sforza V; Nappi A; De Palma R; D'Aiuto E; Berrino L; Bianco R; Ciardiello F
    Clin Cancer Res; 2013 Dec; 19(24):6751-65. PubMed ID: 24122793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
    You B; Chen EX
    J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of ecthyma during therapy with an epidermal growth factor receptor inhibitor.
    Mizuno T; Tanegashima T; Suzuki A; Kuze S; Koyama T
    Eur J Dermatol; 2014; 24(4):511-2. PubMed ID: 25266748
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?
    Lien K; Berry S; Ko YJ; Chan KK
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):81-100. PubMed ID: 25400031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.